13D Filing: Tang Capital Partners LP and Cyclacel Pharmaceuticals Inc. (CYCC)

Page 1 of 7

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC): Kevin C. Tang’s Tang Capital Partners LP filed an amended 13D.

You can check out Tang Capital Management’s latest holdings and filings here.

Please follow Tang Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Tang Capital Management or update its stock holdings.

Follow Kevin C. Tang's Tang Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Tang Capital Partners 0 336,747 0 336,747 336,747 2.8%
Tang Capital Management 0 336,747 0 336,747 336,747 2.8%
Kevin C. Tang 0 336,747 0 336,747 336,747 2.8%

Page 1 of 7 – SEC Filing


Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Cyclacel Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
(CUSIP Number)
Kevin C. Tang
Tang Capital Management, LLC
4747 Executive Drive, Suite 510
San Diego, CA 92121
(858) 200-3830_
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
November 16, 2017
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following pages)

Follow Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)

Page 1 of 7